Tauopathy treatment

Tauopathy treatment involves various strategies aimed at addressing the pathological accumulation and aggregation of tau protein in the brain, which is characteristic of several neurodegenerative diseases, including Alzheimer's disease, frontotemporal dementia, and chronic traumatic encephalopathy. Here are the main approaches currently being explored and developed:

Tauopathy Immunotherapy

Vaccines: Active immunization strategies that stimulate the body’s immune system to produce antibodies against tau protein.

---

2. Small Molecule Inhibitors Kinase Inhibitors: These drugs inhibit the activity of kinases that phosphorylate tau, thereby reducing the hyperphosphorylation and aggregation of tau. Examples include GSK-3β and CDK5 inhibitors. Aggregation Inhibitors: Compounds that prevent tau from aggregating into neurofibrillary tangles. These molecules can interfere with the interactions between tau proteins.

---

3. Tau Clearance Enhancers Proteasome Activation: Enhancing the activity of the ubiquitin-proteasome system to promote the degradation of tau. Autophagy Induction: Activating autophagy pathways to enhance the clearance of tau aggregates from neurons.

---

4. Post-Translational Modification Modulators Acetylation Inhibitors: Compounds that inhibit the enzymes responsible for acetylating tau, such as p300/CBP. By reducing acetylation, these drugs aim to decrease tau aggregation and toxicity. Deacetylase Activators: Enhancing the activity of deacetylases like SIRT1 to promote the removal of acetyl groups from tau.

---

5. Gene Therapy Tau Silencing: Using RNA interference (RNAi) or antisense oligonucleotides (ASOs) to reduce the expression of tau mRNA, thereby lowering tau protein levels in the brain. Gene Editing: CRISPR/Cas9 technology to directly modify or correct tau gene mutations associated with familial tauopathies.

---

6. Neuroprotective Agents Neurotrophic Factors: Compounds like brain-derived neurotrophic factor (BDNF) that support neuron survival and function. Anti-inflammatory Drugs: Reducing neuroinflammation, which is a common feature in tauopathies, to protect neurons from secondary damage.

7. Symptomatic Treatments Cognitive Enhancers: Drugs that improve cognitive function and memory, such as cholinesterase inhibitors and NMDA receptor antagonists.

Behavioral and Physical Therapies: Non-pharmacological interventions, including cognitive training, physical exercise, and occupational therapy, to improve quality of life and daily functioning.

Current Status and Future Directions

Clinical Trials: Several therapeutic approaches are in various stages of clinical development, with ongoing trials assessing the safety and efficacy of different treatments. Combination Therapies: Combining multiple therapeutic strategies to target different aspects of tau pathology and improve treatment outcomes. Biomarker Development: Identifying reliable biomarkers for early diagnosis, disease progression monitoring, and treatment response assessment.

Effective treatment of tauopathies requires a multifaceted approach, combining disease-modifying therapies that target tau pathology with symptomatic treatments to manage clinical manifestations. Ongoing research and clinical trials hold promise for the development of new therapies that can slow or halt disease progression and improve the quality of life for patients with tauopathies.

The perforant pathway projection from layer II of the entorhinal cortex to the hippocampal dentate gyrus is especially important for long term memory formation, and is preferentially vulnerable to developing a degenerative tauopathy early in Alzheimer disease (AD) that may spread over time trans-synaptically. Despite the importance of the perforant pathway to the clinical onset and progression of AD, a therapeutic has not been identified yet that protects it from tau-mediated toxicity.

Results identify systemic rapamycin as a treatment that protects the entorhinal cortex and perforant pathway projection from tau-mediated neurodegeneration, axonal and synapse loss, and neuroinflammatory reactive gliosis. The findings support the potential for slowing the progression of AD by abrogating tau-mediated neurotoxicity at its earliest neuropathological stages [1)].

1)

Siman R, Cocca R, Dong Y. The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy. PLoS One. 2015 Nov 5;10(11):e0142340. doi: 10.1371/journal.pone.0142340. eCollection 2015. PubMed PMID: 26540269.